SCHEMBL21591512

SCHEMBL21591512

CN1CCN(c2cc3occ(CCl)c(=O)c3cc2F)CC1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.43
▸ DRD3 P35462 1/20 0.43
▸ GAA P10253 1/20 0.41
▸ RAD52 P43351 1/20 0.41
▸ KDM4E B2RXH2 5/20 0.40
▸ GLA P06280 1/20 0.40
▸ KMT2A Q03164 5/20 0.39
▸ MEN1 O00255 4/20 0.39
▸ NPC1 O15118 2/20 0.39
▸ HPGD P15428 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ POLB P06746 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ CYP2D6 P10635 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21591476 0.72 CYP11B1 (0.37) ALDH1A1
SCHEMBL21592283 0.70 CYP11B1 (0.41) ALDH1A1DRD3KDM4EKMT2AMEN1
SCHEMBL21591553 0.67 CYP11B1 (0.62) ALDH1A1DRD3GAAKDM4EKMT2A
SCHEMBL10963450 0.66 KMT2A (0.44) ALDH1A1DRD3GAARAD52KDM4E
SCHEMBL14922280 0.64 MAPT (0.53) ALDH1A1DRD3GAARAD52KDM4E
SCHEMBL4241160 0.63 DRD3 (0.60) ALDH1A1DRD3GAARAD52KDM4E
SCHEMBL17321027 0.63 ALOX15 (0.45) ALDH1A1KDM4EKMT2AMEN1NPC1
SCHEMBL14922297 0.63 KDM4E (0.46) ALDH1A1DRD3GAARAD52KDM4E
SCHEMBL22652246 0.63 ALDH1A1 (0.50) ALDH1A1DRD3GAARAD52KDM4E
SCHEMBL17509865 0.63 ALDH1A1 (0.43) ALDH1A1DRD3GAARAD52KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12162863-B2 Modulators of stimulator of interferon genes (STING) Ryvu Therapeutics S.A. (PL) 2024-12-10 — — US disclosed
US-20220402898-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2022-12-22 — — US disclosed
EP-3807264-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2021-04-21 — — EP disclosed
WO-2019238786-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2019-12-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12162863-B2 Modulators of stimulator of interferon genes (STING) STING1, IRF3, CGAS ALDH1A1 4462/4885DRD3 3221/4885GAA 1452/4885
US-20220402898-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) STING1, IRF3, CGAS ALDH1A1 4462/4885DRD3 3221/4885GAA 1452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback